^
Association details:
| Biomarker: | ER mutation |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | Ostarine (enobosarm) (Selective androgen receptor modulator, Androgen receptor modulator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER+/AR+ breast cancer - final results from an international Phase 2 randomized
Published date:
11/17/2020
Excerpt:
In this Phase 2 parallel design study, enobosarm (9 mg and 18 mg) has significant clinical activity and was well tolerated in heavily pretreated patients with ER+/AR+ metastatic breast cancer.
